Compare Otis Worldwide Corp (OTIS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Repligen Corporation Common Stock — how do they compare? Otis Worldwide Corp trades at $69.11 (market cap $25.76B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Otis Worldwide Corp is far larger — about 2.3× Repligen Corporation Common Stock's market cap, and Otis Worldwide Corp pays a 2.6% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 66 Days and Repligen Corporation Common Stock for 0 Days on average.
| OTIS | RGEN | |
|---|---|---|
Market Cap | $25.76B | $11.14B |
Volume | 6,407,907 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $93.62 | $194.57 |
52-Week Low | $64.05 | $102.87 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $33.80B | $11.02B |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $69.11, up 3.54% today but near its 52-week low amid bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B with a 10.17% net margin, though service margins face pressure from labor costs. Analyst consensus is mixed with a $87 price target, while institutional investors show varied positioning through recent acquisitions and sales.
The stock presents a defensive opportunity given its dominant elevator service franchise, but near-term upside is limited by margin pressures and China demand uncertainty. Key risks include execution on service margin expansion and macroeconomic headwinds affecting new equipment orders.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
